These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 31645300)
1. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease. Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300 [TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538 [TBL] [Abstract][Full Text] [Related]
3. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691 [TBL] [Abstract][Full Text] [Related]
4. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081 [TBL] [Abstract][Full Text] [Related]
5. Salmeterol enhances the cardiac response to gene therapy in Pompe disease. Han SO; Li S; Koeberl DD Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193 [TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease. Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824 [TBL] [Abstract][Full Text] [Related]
8. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836 [TBL] [Abstract][Full Text] [Related]
9. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618 [TBL] [Abstract][Full Text] [Related]
10. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. Han SO; Li S; Bird A; Koeberl D Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913 [TBL] [Abstract][Full Text] [Related]
11. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258 [TBL] [Abstract][Full Text] [Related]
12. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease. Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936 [TBL] [Abstract][Full Text] [Related]
13. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase. Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866 [TBL] [Abstract][Full Text] [Related]
14. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373 [TBL] [Abstract][Full Text] [Related]
15. Improved efficacy of a next-generation ERT in murine Pompe disease. Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882 [TBL] [Abstract][Full Text] [Related]
16. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy. Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913 [TBL] [Abstract][Full Text] [Related]